✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
MAAT PHARMA
5599 · RC 808370100 · Active since 2014
Overview
MAAT PHARMA is a 5599 registered , France, since 2014. The company operates in the 7211 sector. With reported revenue of 3.2M EUR in 2024. Its TraceComp score of 77 (B+) indicates solid fundamentals and low apparent risk. With 11 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 808370100
- Legal Form
- 5599
- Registered
- 2014-12-04
Financial Profile
Latest filed accounts: FY 2024
Multi-year financials & ratios
4 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
10 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| HERVE BERNARD NORBERT AFFAGARD | role 65 | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Public Contracts Won
Awarded 1 public-sector contract totalling EUR 624,000 (DECP).
Which public buyers, contract titles, values and award dates.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Patent Portfolio
Active patent holder. 8 patents · 8 active · 8 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Revenue up 44% year-on-year
- Net loss reported in FY 2024
- Altman Z-Score in the distress zone — elevated insolvency risk on the model
Data Sources & Freshness
Data sourced from: bulk register.